Opdivo updates in GBM, melanoma, NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) released several clinical updates for Opdivo nivolumab on Monday, including news that the PD-1 inhibitor missed the primary endpoint in the Phase III CheckMate -143 study to treat recurrent glioblastoma multiforme.

BMS said Opdivo failed to improve overall survival (OS) compared to Avastin bevacizumab in CheckMate -143, but did not provide data. Results are slated to be presented May 7 at the World Federation of Neuro-Oncology Societies meeting in Zurich. Two other studies in GBM, the Phase III CheckMate -498 trial and Phase II CheckMate -548 trial, will continue as planned. Both are evaluating Opdivo as first-line therapy...